menu
    • menu
    [{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Tumor Suppressor Candidate 2 gene","moa":"Pan-kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Genprex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Quaratusugene ozeplasmid","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genprex","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Genprex \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genprex \/ Not Applicable"},{"orgOrder":0,"company":"Heat Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Viagenpumatucel-L","moa":"HSPg96","graph1":"Oncology","graph2":"Phase II","graph3":"Heat Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Heat Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Heat Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Sybleu","sponsor":"Oncology Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Erlotinib","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Sybleu","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Sybleu \/ Oncology Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Sybleu \/ Oncology Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Erlotinib

    Menu

    Erlotinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Heat Biologics

    U.S.A arrow
    BePharma
    Not Confirmed

    Heat Biologics

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Viagenpumatucel-L,Erlotinib

    Therapeutic Area : Oncology

    Study Phase : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process

    Details : New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and other cellular products.

    Product Name : HS-110

    Product Type : Vaccine

    Upfront Cash : Not Applicable

    March 25, 2022

    Lead Product(s) : Viagenpumatucel-L,Erlotinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Sybleu

    Country arrow
    BePharma
    Not Confirmed

    Sybleu

    Country arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Erlotinib,Undisclosed

    Therapeutic Area : Oncology

    Study Phase : Undisclosed

    Sponsor : Oncology Pharma

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Oncology Pharma Signs Licensing Deal with Sybleu to market a Chemotherapeutic Agent in Combination with a Bioa...

    Details : The chemotherapeutic agent of claim is AQ4 & AQ4N. The bioactive agent is derived from the group of TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand.

    Product Name : AQ4

    Product Type : Cytotoxic Drug

    Upfront Cash : Undisclosed

    February 26, 2021

    Lead Product(s) : Erlotinib,Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Undisclosed

    Sponsor : Oncology Pharma

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Genprex

    U.S.A arrow
    BePharma
    Not Confirmed

    Genprex

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Quaratusugene ozeplasmid,Erlotinib

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate

    Details : United States Adopted Names (USAN) Council has approved the non-proprietary name quaratusugene ozeplasmid for GPX-001, formerly called Oncoprex™ immunogene therapy, the Company’s lead drug candidate for non-small cell lung cancer (NSCLC).

    Product Name : GPX-001

    Product Type : Cell and Gene therapy

    Upfront Cash : Not Applicable

    June 25, 2020

    Lead Product(s) : Quaratusugene ozeplasmid,Erlotinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Genprex

    U.S.A arrow
    BePharma
    Not Confirmed

    Genprex

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tumor Suppressor Candidate 2 gene,Osimertinib Mesylate,Erlotinib

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Genprex to Focus Its Clinical Efforts on Oncoprex with Osimertinib

    Details : The company’s current Phase I/II clinical trial utilizes the combination of the EGFR inhibitor erlotinib and Oncoprex against NSCLC.

    Product Name : Undisclosed

    Product Type : Cell and Gene therapy

    Upfront Cash : Not Applicable

    February 05, 2020

    Lead Product(s) : Tumor Suppressor Candidate 2 gene,Osimertinib Mesylate,Erlotinib

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth